Evaluation of disease modifying activity of Colchicum luteum Baker in experimental arthritis
Department of Pharmacology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India. Journal of ethnopharmacology
(Impact Factor: 3).
10/2010; 133(2):303-7. DOI: 10.1016/j.jep.2010.09.027
Colchicum luteum (CL) has been traditionally used in the Unani system of medicine as a chief ingredient of many polyherbal formulations for the treatment of joint pain and rheumatoid arthritis (RA).
To evaluate the antiarthritic activity of CL hydroalcoholic extract (CLHE) in formaldehyde and complete Freund's adjuvant (CFA) induced arthritis.
Arthritis was induced by administration of either formaldehyde (2% v/v) or CFA into the subplantar surface of the hind paw of the animal. Joint swelling was measured on days 8, 9 and 10 in formaldehyde induced arthritis and days 3, 7, 14 and 21 in CFA induced arthritis. In order to evaluate the effect of CLHE on disease progression, serum TNF-α level and synovial expression of proinflammatory mediators (TNF-R1, IL-6 and IL-1β) was determined in CFA induced arthritis.
CLHE produced a significant and dose dependent inhibition of joint swelling during the entire duration of the study in both, formaldehyde and CFA induced arthritis. Serum TNF-α level was also reduced significantly in a dose dependent manner in all the CLHE treated groups. The expression of proinflammatory mediators (TNF-R1, IL-6 and IL-1β) was also found to be less in the CLHE treated group as compared to control.
We believe that the antiarthritic activity of CLHE was due to its modulatory effect on the expression of proinflammatory cytokine in the synovium. Our results contribute towards validation of the traditional use of CL in the treatment of RA and other inflammatory joint disorders.
Available from: PubMed Central
- "Dosage selection for fractions of plant (ethyl acetate, 100 mg/kg and n-butanol, 200 mg/kg) was based on the previous studies conducted by our research group . The antiarthritic potential of EAPA and BPA was initially investigated against formaldehyde- induced paw edema, which is one of the most common methods for screening of antiarthritic agents . The localized inflammation, induced by injection of formaldehyde into rat paw, is biphasic in nature . "
[Show abstract] [Hide abstract]
The present investigation was designed to evaluate antiarthritic potential of fractions of hydroalcoholic extract from leaves of P. alba.
Materials and methods:
Plumeria alba L. leaves were extracted with hydroalcohol (30 : 70) to obtain hydroalcoholic extract of P. alba. This extract was further fractionated with solvents ethyl acetate and n-butanol to obtain EAPA and BPA, respectively. These fractions were tested against formaldehyde and Freund's complete adjuvant (FCA) induced arthritis. Arthritis assessment, paw volume, body weight, motor incoordination, and nociceptive threshold were measured. On day 21, the animals were sacrificed and histopathology was done.
The 100 and 200 mg/kg doses of EAPA and BPA caused a significant (P ≤ 0.05-0.01) reduction in paw swelling in both models. Erythrocyte sedimentation rate (ESR) and spleen weight decreased significantly (P < 0.01) in arthritic rats treated with extracts. There was significant (P < 0.05) improvement in thymus weight in EAPA treated rats whereas significant (P < 0.01) improvement was also seen in haemoglobin level (Hb) in diclofenac treated group. Motor incoordination and nociceptive threshold were also significantly (P ≤ 0.05-0.01) improved.
The present study suggests that Plumeria alba L. has protective activity against arthritis and supports the traditional use of P. alba for rheumatism and other inflammatory diseases.
BioMed Research International 06/2014; 2014:474616. DOI:10.1155/2014/474616 · 1.58 Impact Factor
Available from: Dr. Shruthi SD
- "Arthritis is an autoimmune disease in which there is joint inflammation, synovial proliferation and destruction of articular cartilage (Tripathi 2003). It is a common disease having peak incidence in 3 rd to 4 th decades of life with 3-5 times higher preponderance in female (Mohan 2000). Its prevalence depends upon age (Pandey 2010). "
[Show abstract] [Hide abstract]
ABSTRACT: Kirganelia reticulata is a medicinal shrub which has been valued for centuries in ayurvedic medicine. In vitro, in vivo and in silico antiarthritic activity of a phytoconstituent, polyprenol isolated from the leaves of Kirganelia reticulata was screened. Various in vitro models such as inhibition of protein denaturation, effect of membrane stabilization and proteinase inhibitory actions were studied. Polyprenol with two different concentrations (100µg/ml and 250µg/ml) was used and results were compared with acetyl salicylic acid. The in vivo antiarthritic activity of polyprenol was evaluated against formaldehyde induced arthritis in albino rats. The course of treatment was followed for over and 4 weeks post inoculation period using health, clinical and behavioural methods of study. Estimation of change in body weight was considered as health parameters and clinical observations included paw edema volume, change in the movements was studied in behavioral observations. The effect of polyprenol was compared with standard drug aspirin. HIF-2α promotes degradative pathways that foster osteoarthritis. The articular cartilage resides in hypoxic, avascular conditions within the synovial joint. Chondrocytes, cells of the articular cartilage are affected by various forms of stress. The biological role of this mediator is clearly understood thus offering new target for inhibiting incurable osteoarthritis. The inhibitory effect of polyprenol was studied using Autodock and efficiency was compared with standard drug in terms of interation and binding. The isolated compound polyprenol showed dose dependent activity which was found to be significant to that of the standard drugs and supports the traditional use of plant for rheumatism.
Available from: Neeraj Sethiya
- "Researchers have found many new mediators viz, TNF-毩, IL-1 and enzymes which take part directly or indirectly in perpetuation of RA  . Previous reports indicated that hydroalcoholic extract of root of Hemidesmus indicus R.Br. "
[Show abstract] [Hide abstract]
ABSTRACT: To investigate the protective effects of hydroalcoholic and its fractions from roots of Hemidesmus indicus on arthritis in in vitro models of rodents.
Preliminary phytochemical analysis and thin-layer chromoatography were performed to analyze constituents of hydroalcoholic extract and its three fraction namely ethyl acetate fraction, chloroform fraction and residual fraction of root of Hemidesmus indicus. Arthritis rats models were established by Complete Freund's Adjuvant. The parameters including paw edema, body weight, arthritic index, erythrocyte sedimentation rate, serum rheumatoid factor, serum C-reactive protein, serum nitrite level, and histopathology of synovial joints were observed. Methotrexate was taken as positive control.
Rats treated with hydroalcoholic extract (450 mg/kg, p.o.), ethyl acetate (75 mg/kg, p.o.), chloroform (60 mg/kg, p.o) and residual fractions (270 mg/kg, p.o.), showed significant decrease in physical and biochemical parameters compared with arthritic model rats. Hydroalcoholic extract and its ethyl acetate fraction of Hemidesmus indicus showed significantly higher anti-arthritic activity than chloroform and residual fraction. Histopathological analysis demonstrated that both of hydroalcoholic extract and its ethyl acetate fraction had comparable anti-arthritic activity with methotrexates.
The present study suggests that Hemidesmus indicus has protective activity against arthritis and the activity might be attributed to presence of terpenoid in hydroalcoholic extract, as well as in ethyl acetate fraction.
Asian Pacific Journal of Tropical Medicine 02/2012; 5(2):130-5. DOI:10.1016/S1995-7645(12)60011-X · 0.93 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.